Pegunigalsidase alfa-iwxj: Revision history

23 May 2024

• curprev 04:3804:38, 23 May 2024‎ Alen Antony talk contribs‎ 5,698 bytes +1,255‎ No edit summary
• curprev 02:3402:34, 23 May 2024‎ Alen Antony talk contribs‎ 4,443 bytes +83‎ No edit summary
• curprev 02:3202:32, 23 May 2024‎ Alen Antony talk contribs‎ 4,360 bytes +931‎ No edit summary
• curprev 02:1802:18, 23 May 2024‎ Alen Antony talk contribs‎ 3,429 bytes +1,339‎ No edit summary

22 May 2024

• curprev 04:2604:26, 22 May 2024‎ Alen Antony talk contribs‎ 2,090 bytes +459‎ No edit summary
• curprev 04:0604:06, 22 May 2024‎ Alen Antony talk contribs‎ 1,631 bytes +752‎ No edit summary
• curprev 03:5703:57, 22 May 2024‎ Alen Antony talk contribs‎ 879 bytes +55‎ No edit summary

21 May 2024

• curprev 21:2521:25, 21 May 2024‎ Alen Antony talk contribs‎ 824 bytes +824‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=pegunigalsidase alfa-iwxj |indicationType=treatment |indication=Fabry's disease in adults |hasBlackBoxWarning=Yes |adverseReactions=infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, and sinusitis. |blackBoxWarningTitle=HYPERSENSITIVITY REACTIONS including Anaphylaxis |blackBoxWarningBody=Patients may experience hypersensitivity reaction including a..."